Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancer

20 Dec 2024

Abstract excerpt

Recent studies suggest that glucocorticoid receptor (GR) activation can cause enzalutamide resistance in advanced prostate cancer (PCa) via functional bypass of androgen receptor (AR) signaling. However, the specific molecular mechanism(s) driving this process remain unknown. We have previously reported that the transcription factor TBX2 is over-expressed in castrate-resistant prostate cancer (CRPC). In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hormonal and reproductive studies
Share to Prostate Cancer Treatment and Research
Share to Sexual Differentiation and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39702503
DOI: 10.1038/s41388-024-03252-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A TBX2-driven signaling switch from androgen receptor to glucocorticoid receptor confers therapeutic resistance in prostate cancerPMID 39702503Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancerSemantic proximity Read ↗

SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axisSemantic proximity Read ↗

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancerSemantic proximity Read ↗

Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer CellsSemantic proximity Read ↗

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.Semantic proximity Read ↗

ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate CancerSemantic proximity Read ↗

ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancerSemantic proximity Read ↗

The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancerSemantic proximity Read ↗

Glucocorticoid receptor action in prostate cancer: the role of transcription factor crosstalkSemantic proximity Read ↗

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancerSemantic proximity Read ↗

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.